Sigyn Therapeutics (OTCMKTS:SIGY) Shares Down 41.5% – Should You Sell?

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY)’s stock price dropped 41.5% during mid-day trading on Friday . The stock traded as low as $0.2523 and last traded at $1.00. Approximately 6,129 shares traded hands during mid-day trading, an increase of 16,901% from the average daily volume of 36 shares. The stock had previously closed at $1.7099.

Sigyn Therapeutics Stock Down 41.5%

The company has a market capitalization of $1.61 million, a P/E ratio of -0.24 and a beta of -0.72. The company has a 50-day moving average of $1.81 and a two-hundred day moving average of $2.57.

Sigyn Therapeutics (OTCMKTS:SIGY) last posted its quarterly earnings data on Tuesday, December 2nd. The company reported $0.49 earnings per share (EPS) for the quarter. During the same period in the prior year, the company posted $0.24 earnings per share.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.